SCHEMBL8296133

SCHEMBL8296133

CCCCCC(C(=O)NO)C(=O)Nc1ccccn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
ALOX12 P18054 1/20 0.53
ALDH1A1 P00352 2/20 0.49
POLB P06746 1/20 0.49
HDAC8 Q9BY41 6/20 0.48
HDAC3 O15379 4/20 0.48
HDAC6 Q9UBN7 4/20 0.48
HDAC1 Q13547 3/20 0.48
HDAC2 Q92769 3/20 0.48
HDAC4 P56524 2/20 0.48
HDAC7 Q8WUI4 2/20 0.48
HDAC10 Q969S8 2/20 0.48
HDAC11 Q96DB2 2/20 0.48
HDAC9 Q9UKV0 2/20 0.48
HDAC5 Q9UQL6 2/20 0.48
GAA P10253 1/20 0.47
NPC1 O15118 1/20 0.45
PKM P14618 1/20 0.45
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6462222 0.83 HTT (0.57) HTTSMN1; SMN2ALOX12ALDH1A1POLB
SCHEMBL8644189 0.81 TSHR (0.58) HTTSMN1; SMN2ALOX12ALDH1A1POLB
SCHEMBL8145665 0.80 HDAC2 (0.62) HTTSMN1; SMN2ALDH1A1POLBHDAC8
SCHEMBL8296171 0.79 HDAC2 (0.64) HTTSMN1; SMN2ALDH1A1HDAC8HDAC3
SCHEMBL8296679 0.77 HDAC8 (0.47) HTTSMN1; SMN2HDAC8HDAC3HDAC6
SCHEMBL21755154 0.76 POLB (0.57) HTTSMN1; SMN2ALOX12ALDH1A1POLB
SCHEMBL8296136 0.76 LMNA (0.57) POLBHDAC8HDAC3HDAC6HDAC1
SCHEMBL13175364 0.75 LMNA (0.60) POLBHDAC8HDAC3HDAC6HDAC1
SCHEMBL7418597 0.74 POLB (0.55) HTTSMN1; SMN2ALOX12ALDH1A1POLB
SCHEMBL22610225 0.74 HDAC3 (0.73) HTTSMN1; SMN2ALOX12ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2322160-A1 Methods of inducing terminal differentiation Merck HDAC Research, LLC (US) 2011-05-18 EP disclosed
EP-2266552-A2 Methods of inducing terminal differentiation Merck HDAC Research, LLC (US) 2010-12-29 EP disclosed
EP-2226072-A1 Combinations of suberoylanilide hydroxamic acid and antimetbolic agents for treating cancer Aton Pharma, Inc. (US) 2010-09-08 EP disclosed
EP-2082737-A2 Methods of inducing terminal differentiation Merck HDAC Research, LLC (US) 2009-07-29 EP disclosed
WO-2005023179-A2 COMBINATION METHODS OF TREATING CANCER ATON PHARMA, INC. (US) 2005-03-17 WO disclosed
WO-2003075839-A2 METHODS OF INDUCING TERMINAL DIFFERENTIATION ATON PHARMA, INC. (US) 2003-09-18 WO disclosed